$新桥生物(NBP)$ MRK

Dana Graybosch: You announced with the transition from I-Mab to NovaBridge that you were going to do a Hong Kong IPO. Could you help us understand that process?

Dana Graybosch： 你们在宣布从I-Mab过渡到NovaBridge时表示打算在香港IPO。您能帮助我们了解一下目前的进展吗？

Sean: There has been an adjustment of our Hong Kong IPO plan, mostly driven by the additional requirement of documents from CSRC (China Securities Regulatory Commission). As we speak we are preparing those documents. Another thing I will say is our stock is not reflecting our true value based on the strength of the data and our pipeline. We want to give a window for our stock price to reflect that inherent value. At the current level, it's far from the level that I'm willing to pull the trigger to go for an IPO.

Sean： 我们的香港IPO计划有所调整，主要是因为中国证监会（CSRC）对文件提出了额外的要求。我们目前正在准备这些文件。我想说的另一件事是，基于我们的数据和管线实力，我们目前的股票并没有反映出真正的价值。我们希望给股票价格留出一个窗口期，以反映我们管线的内在价值。在当前的估值水平，我远没有扣动扳机去进行IPO的意愿。